Literature DB >> 21380817

Role of nonsteroidal anti-inflammatory drug-activated gene-1 in docetaxel-induced cell death of human colorectal cancer cells with different p53 status.

Il-Yeob Kim1, Su-Young Park, Youra Kang, Dinesh Thapa, Han Gon Choi, Jung-Ae Kim.   

Abstract

Nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) expression is upregulated not only by NSAIDs such as sulindac sulfide, but also by several antitumorigenic dietary compounds, suggesting that NAG-1 is a specific target for the development of effective anticancer agents. Despite being a downstream target of p53, NAG-1 induction is both p53-dependent and p53-independent. It is not clear whether NAG-1 induction is the responsible factor in cancer cell apoptosis with mutated p53. In this study, we report that NAG-1 induction alone cannot determine apoptotic cell fate in colon cancer cells. Although docetaxel induced an increase in NAG-1 and apoptosis in both HCT-116 (wild-type p53) and HT-29 (mutant p53) colon cancer cells, NAG-1 knockdown with siRNA prevented docetaxel-induced cell death in only HCT-116 cells. Docetaxel decreased Bcl-2 in HCT-116 cells, which have functionally active p53, according to luciferase reporter gene analyses, and docetaxel-induced cell death and changes in Bcl-2 and NAG-1 expression were blocked by PFT-α, a p53 inhibitor. In HT-29 cells with functionally inactive p53, the docetaxel-induced Bcl-xL decrease, NAG-1 increase, and cell death were not blocked by PFT-α. On the other hand, sulindac sulfide at concentrations that significantly induced NAG-1 did not decrease cell viability comparable to docetaxel, and it did not affect the level of p53, Bax, Bcl-2, and Bcl-xL in either cell line. The present study demonstrates that p53-dependent NAG-1 induction is linked to cell death and that NAG-1 induction without accompanying alteration of antiapoptosis protein Bcl-2 family members may not lead to cancer cell death.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21380817     DOI: 10.1007/s12272-011-0219-8

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  4 in total

1.  Elevated growth differentiating factor 15 expression predicts long-term benefit of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy in patients with oral cancer.

Authors:  Xiao Tang; Yong-Jie Hu; Wu-Tong Ju; Yong Fu; Wen-Wen Sun; Ying Liu; Yi-Ran Tan; Li-Zhen Wang; Jiang Li; Yao-Yao Tu; Chen-Ping Zhang; Zhi-Yuan Zhang; Lai-Ping Zhong
Journal:  Oncol Lett       Date:  2018-03-22       Impact factor: 2.967

2.  RNPC1, an RNA-binding protein and a p53 target, regulates macrophage inhibitory cytokine-1 (MIC-1) expression through mRNA stability.

Authors:  Tiffany Yin; Seong-Jun Cho; Xinbin Chen
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

3.  ZeOncoTest: Refining and Automating the Zebrafish Xenograft Model for Drug Discovery in Cancer.

Authors:  Carles Cornet; Sylvia Dyballa; Javier Terriente; Valeria Di Giacomo
Journal:  Pharmaceuticals (Basel)       Date:  2019-12-24

Review 4.  NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species.

Authors:  Rajeshwary Ghosh; Azra Alajbegovic; Aldrin V Gomes
Journal:  Oxid Med Cell Longev       Date:  2015-09-20       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.